Related Experiment Video

Updated: Mar 20, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy

Ke-Qiong Deng1,2,3, Aibing Wang4, Yan-Xiao Ji1,2,3

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Nature Communications
|June 2, 2016
PubMed

Insights

Suppressor of IKK-epsilon (SIKE) protects against pathological cardiac hypertrophy by inhibiting the TBK1/AKT pathway. This discovery in multiple species suggests SIKE as a potential therapeutic target for heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Immunology

Background:

  • Pathological cardiac hypertrophy is a major global health concern with poorly understood molecular underpinnings.
  • Identifying novel regulators of cardiac remodeling is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of Suppressor of IKK-epsilon (SIKE) in pathological cardiac hypertrophy.
  • To elucidate the molecular mechanisms by which SIKE regulates cardiac remodeling.
  • To assess the therapeutic potential of SIKE in cardiac hypertrophy and heart failure.

Main Methods:

  • Utilized Sike-deficient and Sike-overexpressing transgenic mice models.
  • Investigated the interaction between SIKE and TANK-binding kinase 1 (TBK1).
  • Analyzed the impact on the TBK1/AKT signaling pathway.
  • Validated findings in rodent and non-human primate models.

Main Results:

  • SIKE deficiency led to cardiac hypertrophy and heart failure in mice.
  • Overexpression of SIKE protected against hypertrophic stimuli.
  • SIKE directly inhibits the TBK1/AKT signaling pathway.
  • SIKE's cardioprotective effects were confirmed in rats and monkeys.

Conclusions:

  • SIKE acts as a negative regulator of pathological cardiac hypertrophy and remodeling.
  • SIKE exerts its anti-hypertrophic effects by inhibiting the TBK1/AKT axis.
  • SIKE represents a promising therapeutic target for treating cardiac hypertrophy and heart failure.

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes12:49

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

25.6K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
640
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
550
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K